A Look At Progyny (PGNY) Valuation After A Steep Three Month Share Price Pullback

Progyny stock performance sets the stage for closer review

Progyny (PGNY) has been under pressure, with the share price showing a 1.5% decline over the past day, a 5.8% decline over the past month, and a 35.5% decline over the past 3 months.

These moves, alongside recent financial figures such as US$1.29b in revenue and US$58.52m in net income, are prompting some investors to reassess what they are paying for the company’s fertility and family benefits business.

See our latest analysis for Progyny.

With the share price at US$16.60 and a year to date share price return of a 35.5% decline, momentum has clearly faded, and the 1 year total shareholder return of a 26.55% decline underlines how sentiment has cooled despite Progyny’s scale in US fertility benefits.

If Progyny’s recent pullback has you rethinking your watchlist, it can be helpful to see what else is moving in related areas such as healthcare AI, starting with 36 healthcare AI stocks.

With Progyny trading at US$16.60, generating US$1.29b in revenue and US$58.52m in net income, the key question is whether this selloff leaves the stock undervalued or if the market already reflects its future growth potential.

Most Popular Narrative: 46.3% Undervalued

Progyny’s most followed narrative sets a fair value of $30.91 per share, compared with the last close at $16.60. This frames a wide valuation gap that hinges on assumptions about future growth and profitability.

Investment in an integrated women's health platform (including new services such as pelvic floor therapy, leave navigation, and enhanced digital engagement) positions Progyny to cross sell adjacent products, resulting in higher share of wallet with current clients and additional revenue streams, supporting both topline and margin expansion.

Read the complete narrative.

Want to see what kind of revenue growth, margin uplift, and future earnings multiple are needed to justify that gap? The narrative sets out a detailed earnings path, a richer product mix, and a specific profit profile that all need to line up for $30.91 to make sense.

Result: Fair Value of $30.91 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there are still clear swing factors, including employer cost cutting that could limit fertility benefit adoption and rising competition that might pressure Progyny’s margins and client growth.

Find out about the key risks to this Progyny narrative.

Another View: Market Pricing Looks Less Generous

The first narrative leans on future cash flows to argue Progyny could be materially undervalued, yet today the shares trade on a P/E of 22.2x versus 18.2x for peers and a fair ratio of 21.8x. That premium hints at less cushion if expectations are wrong, so which signal do you trust?

For a closer look at how this earnings based view is built and what might need to change for the current price to better line up with the fair ratio, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The recent pullback and mixed valuation signals might leave you conflicted. Do not wait to review the details for yourself and weigh the upside case in the 3 key rewards

Ready to hunt for your next opportunity?

If Progyny is already on your radar, do not stop there. Broadening your ideas list can sharpen your decisions and highlight opportunities you might otherwise miss.

• Spot potential bargains early by scanning screener containing 25 high quality undiscovered gems that pair quality fundamentals with room for market attention to catch up.
• Focus on financial resilience and consistent balance sheet strength using the solid balance sheet and fundamentals stocks screener (40 results) to surface companies with sturdier foundations.
• Prioritise stability and lower volatility by screening for 68 resilient stocks with low risk scores that may help anchor a more balanced portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com